Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Algert Global LLC

Algert Global LLC trimmed its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 36.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 164,839 shares of the medical technology company’s stock after selling 96,328 shares during the period. Algert Global LLC owned about 0.12% of Alphatec worth $1,513,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Comerica Bank raised its stake in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. R Squared Ltd purchased a new position in shares of Alphatec in the fourth quarter worth about $29,000. Nisa Investment Advisors LLC raised its holdings in Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 4,234 shares during the last quarter. Quarry LP lifted its stake in Alphatec by 79.2% in the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC acquired a new position in shares of Alphatec during the 4th quarter worth approximately $50,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alphatec

In other news, CEO Patrick Miles sold 12,691 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $10.64, for a total value of $135,032.24. Following the transaction, the chief executive officer now owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This represents a 0.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Scott Lish sold 23,183 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $12.03, for a total value of $278,891.49. Following the sale, the chief operating officer now owns 844,494 shares of the company’s stock, valued at approximately $10,159,262.82. The trade was a 2.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 126,945 shares of company stock valued at $1,416,352 in the last quarter. Corporate insiders own 22.80% of the company’s stock.

Alphatec Trading Down 4.1 %

NASDAQ ATEC opened at $12.22 on Friday. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $12.82. The firm has a 50 day simple moving average of $10.50 and a 200-day simple moving average of $10.10. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -9.55 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The business had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business’s revenue was up 22.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) EPS. Equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ATEC has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler restated an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Alphatec in a report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.89.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.